Life Science Investing NRx Pharmaceuticals, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Life Science Investing NRx Pharmaceuticals, Inc. to Report Third Quarter 2025 Financial Results on November 17, 2025
Life Science Investing HOPE Therapeutics, Inc., an NRx Pharmaceuticals Subsidiary, Announces First-in-Florida Initiation of One Day Depression Treatment in Partnership with Ampa Health
Life Science Investing HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. Announce Inclusion of Cohen & Associates, LLC of Sarasota, FL into the HOPE Network and Appointment of Dr. Rebecca Cohen as HOPE Medical Director
Life Science Investing NRx Pharmaceuticals, Inc. to Present at Noble Capital Markets October 2025 Emerging Growth Virtual Equity Conference
Life Science Investing NRx Pharmaceuticals, Inc. Re-Files Abbreviated New Drug Application for KETAFREE, Preservative-Free IV Ketamine
Life Science Investing NRx Pharmaceuticals, Inc. Receives Notification of US Food and Drug Administration Approval of Suitability Petition for NRx's Proposed Strength of Preservative-Free Ketamine
Life Science Investing HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. Complete the Acquisition of Dura Medical; Initial Acquisition in Network of Interventional Psychiatry Clinics
Life Science Investing NRx Pharmaceuticals to Participate in a Fireside Chat at H.C. Wainwright's 27th Annual Global Investment Conference on Monday, September 8th
Stardust Metal Uncovers Large, Never-Drilled Ultramafic Target Adjacent to High-Grade Kerr Addison in Kirkland Lake
E-Power Resources Appoints New CEO and Expands Advisory Teams; Focus on Agressive Strategy for Tetepisca Graphite Project
Standard Uranium Receives Drill Permits and Initiates Ground Gravity Survey on the Corvo Uranium Project
